You are here: Industry Insights > Sunovion

News List

Sunovion submits NDA for dasotraline to US FDA to treat ADHD patients pharmaceufical-technology
September 05, 2017
Sunovion Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for dasotraline to treat patients with attention deficit hyperactivity disorder (ADHD).
Sunovion Submits NDA for Dasotraline for the Treatment of ADHD Patients americanpharmaceuticalreview.
September 01, 2017
Sunovion Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for dasotraline, a novel investigational, dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of children,
Sunovion Divests Asthma and Allergy Products to Covis americanpharmaceuticalreview
July 18, 2017
Sunovion has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide products ALVESCO Inhalation Aerosol, OMNARIS Nasal Spray, and ZETONNA Nasal Aerosol to Covis Pharma. Ciclesonides are included in the corticosteroi
Sunovion Announces FDA Acceptance for Review of sNDA for Latuda for Bipolar Depression americanpharmaceuticalreview
July 04, 2017
Sunovion Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the expanded use of Latuda (lurasidone HCI) in children...
Sunovion Submits sNDA to FDA for Use of APTIOM® for the Treatment of Partial-Onset Seizures in Child americanpharmaceuticalreview
March 14, 2017
Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication for its antiepileptic drug (AED) APTIOM® (eslicarbazepine acetate) to include use as monotherapy or a

Previous page 1 2 Next page